Results 171 to 180 of about 39,038 (256)

Blood Pressure‐Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real‐World Data Analysis

The Journal of Clinical Hypertension, Volume 28, Issue 2, February 2026.
ABSTRACT Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have demonstrated blood pressure (BP)‐lowering effects; however, most studies included patients taking antihypertensive medications. Using real‐world Japanese data, we assessed factors associated with SGLT2 inhibitor‐mediated BP reduction in patients not taking antihypertensive therapy.
Reina Ito, Michihiro Satoh, Hideaki Hashimoto, Hiroki Nobayashi, Seiya Izumi, Maya Toyama, Yutaro Iwabe, Yuya Suzuki, Takuo Hirose, Shingo Nakayama, Takahisa Murakami, Masato Sasaki, Hirohito Metoki   +12 more
wiley   +1 more source

Incidence of treatment intensification based on HbA1c trends in people with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 321-329, February 2026.
We conducted this study to examine the incidence of treatment intensification in response to changes in the HbA1c levels in people with type 2 diabetes. Of the 5,683 patients, 4,553 (80.1%) did not undergo treatment intensification at the second consultation.
Erika Sugito, Takehiro Sugiyama, Ryotaro Bouchi, Akiyo Tanabe, Kohjiro Ueki, Mitsuru Ohsugi   +5 more
wiley   +1 more source

Identification and rescue of congenital hyperinsulinism-associated ABCC8 mutations that impair K_ATP channel trafficking. [PDF]

J Biol Chem
ElSheikh A, Kuo YY, Boodhansingh KE, Yang Z, Stanley CA, De Leon DD, Shyng SL.   +6 more
europepmc   +1 more source

Lower glycemic status was associated with pancreatic cancer risk in prediabetes, but not in diabetes: A nationwide cohort study

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 338-346, February 2026.
In a nationwide Korean cohort of nearly 3 million adults, higher fasting blood glucose within the prediabetic range—but not glycemic control among people with diabetes—was associated with increased pancreatic cancer risk, highlighting the importance of optimal glucose control in nondiabetic populations.
Dong‐Hoe Koo, Jin‐Hyung Jung, Kyungdo Han, Cheol‐Young Park   +3 more
wiley   +1 more source

Diabetes mellitus <i>HNF4A</i>-MODY in children from the Russian population: clinical and genetic features. [PDF]

Front Endocrinol (Lausanne)
Sechko EA, Laptev DN, Koltakova MP, Khusainova RI, Minniakhmetov IR, Kuraeva TL, Eremina IA, Titovich EV, Bezlepkina OB, Peterkova VA.   +9 more
europepmc   +1 more source

The role of membrane excitability in pancreatic β-cell glucotoxicity [PDF]

, 2019
Nichols, Colin G., Remedi, Maria S., Shyr, Zeenat A., Wang, Zhiyu, York, Nathaniel W.   +4 more
core   +1 more source

Diabetic peripheral neuropathy as measured using a point‐of‐care sural nerve conduction device is associated with a faster decline in renal function in patients with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 291-300, February 2026.
Point‐of‐care assessment of diabetic peripheral neuropathy with DPN‐Check® was independently associated with a faster decline in renal function in type 2 diabetes, highlighting its potential as a tool to identify patients at high risk of kidney disease progression. ABSTRACT Aims/Introduction Diabetic peripheral neuropathy (DPN) is a common complication
Tatsuya Fukuda, Akiko Fujii, Taro Akihisa, Naoya Otsubo, Tetsuya Yamada, Chisato Maki   +5 more
wiley   +1 more source

The difference in type 2 diabetes care between the National Health Insurance beneficiaries and public assistance recipients in Japan: A retrospective cohort study based on claims data in a municipality

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 347-359, February 2026.
We examined the differences in type 2 diabetes care between public assistance recipients and National Health Insurance beneficiaries in Japan by using claims data from a municipality. Public assistance might improve diabetes care process, but not fully health outcomes.
Takuya Yamaoka, Takehiro Sugiyama, Daisuke Nishioka, Naoki Kondo, Nanako Tamiya   +4 more
wiley   +1 more source

Impact of Adding GLP-1 Receptor Agonists to Insulin Therapy on Cardiovascular and Microvascular Outcomes in Type 2 Diabetes: A Nationwide Cohort Study from Taiwan. [PDF]

Pharmaceuticals (Basel)
Yen FS, Wei JC, Sung CY, Li PY, Tsai FJ, Hsu CC, Hwu CM.   +6 more
europepmc   +1 more source

Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 214-226, February 2026.
Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement.
Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki   +4 more
wiley   +1 more source